認知症治療の市場規模、シェア、動向分析レポート：適応症別、薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント予測、2024年～2030年

認知症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の認知症治療市場規模は、2024年から2030年にかけて7.68%のCAGRを記録し、2030年までに281億1,000万米ドルに達すると予測されています。

認知症患者の増加、新薬の導入、効果的な治療法を開発するための市場関係者や研究機関の関与の増加は、市場成長を促進する主な要因の一部です。2023年9月に発表されたCross River Therapyのデータによると、英国におけるアルツハイマー病（AD）の有病率は人口10万人当たり約42.70人で、人口1人当たりの患者数が2番目に多い国となっています。

認知症治療のための啓発キャンペーンや新規治療法を開発するための研究活動を支援するために、政府や非政府機関が実施する有利なイニシアチブの増加は、市場の成長を促進すると予想されます。例えば、2022年2月、マギル大学の認知症教育プログラムは、カナダ公衆衛生局から資金提供を受け、病気に関する認知度を高めるための15のプロジェクトを開始しました。認知症コミュニティ投資（DCI）は75万8,430米ドルを投資し、介護者の間に認知度を広めるために、同大学の成人学習者向け10週間にわたる10オンラインモジュール（TOTAL）eラーニングを支援する予定です。

学術研究機関はさらに、さまざまなタイプの認知症の研究や、全体的な疾病負担を軽減するための効果的な治療薬の開発などの研究活動に取り組んでいます。例えば、2024年2月、コロラド大学アンシュッツ・メディカル・キャンパスの研究者は、Mdm2タンパク質と治験中の抗がん剤ヌートリンが、アルツハイマー病に関連するシナプスと樹状突起スパインの破壊を防ぐことができることを発見しました。さらに2023年12月、ペンシルバニア大学ペレルマン医学部の前臨床研究で、シャペロン分子が脳の老化や記憶障害を含む病気の兆候を逆転させることができる特定のタンパク質を処方することが示されました。

新興国市場のプレーヤーは、認知症に対する効果的で安全な治療法を開発する能力を高めるために、地域のプレーヤーや研究機関と協力しています。2021年2月、Exscientiaとオックスフォード大学はアルツハイマー病の治療法開発で提携しました。さらに、エーザイ株式会社とバイオジェン社は、認知症に対する効果的な治療法を早期に開発するために提携しました。これらの企業はアデュカヌマブとレカネマブを共同開発しました。両社は世界中の主要な規制当局からこれらの薬剤の市場承認を受けています。

認知症治療市場レポートハイライト

• AD認知症は、AD認知症の高い有病率と承認薬により、2023年には60.11%のシェアを占め、適応症セグメント市場を独占しました。
• レビー小体型認知症（LBD）セグメントは、発症率と重症度の増加により、2024年から2030年にかけて最も速いCAGRで成長すると予測されます。
• コリンエステラーゼ阻害薬セグメントは、経口および経皮パッチの処方率が高いことから、2023年に最大のシェアを占めました。
• 配合剤セグメントは、配合剤の有効性と採用率の増加により、2024年から2030年にかけて最も速いCAGRを経験すると予測されています。
• 注射薬投与経路セグメントは、生物学的製剤のイントロダクションと有望な注射薬のパイプラインの存在により、2024年から2030年にかけて最も速いCAGRを記録すると予測されます。
• 2023年の世界市場は北米が支配的であったが、これは同地域の疾患有病率の高さ、強力な市場プレイヤーの存在、より良い償還政策などの要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 認知症治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 認知症治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 認知症治療市場：適応症の推定・動向分析

• 世界の認知症治療市場：適応症のダッシュボード
• 世界の認知症治療市場：適応症の変動分析
• 世界の認知症治療市場：適応症別、収益 2018-2030年
• アルツハイマー病認知症
• 血管性認知症
• レビー小体型認知症
• 前頭側頭型認知症（FTD）
• パーキンソン病認知症
• その他

第5章 認知症治療市場：薬剤クラスの推定・動向分析

• 世界の認知症治療市場：薬剤クラスのダッシュボード
• 世界の認知症治療市場：薬剤クラスの変動分析
• 世界の認知症治療市場、薬剤クラス別、収益 2018-2030年
• コリンエステラーゼ阻害剤
• NMDA受容体拮抗薬
• MAO阻害剤
• 併用薬
• その他

第6章 認知症治療市場：投与経路の推定・動向分析

• 世界の認知症治療市場：投与経路のダッシュボード
• 世界の認知症治療市場：投与経路の変動分析
• 世界の認知症治療市場：投与経路別、収益 2018-2030年
• 経口
• 経皮パッチ
• 注射

第7章 認知症治療市場：流通チャネルの推定・動向分析

• 世界の認知症治療市場：流通チャネルのダッシュボード
• 世界の認知症治療市場：流通チャネルの変動分析
• 世界の認知症治療市場：流通チャネル別、収益 2018-2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 認知症治療市場：地域の推定・動向分析

• 地域のダッシュボード
• 市場規模、予測・動向分析、2018-2030年
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Eisai Co., Ltd.
  • Lilly
  • Novartis AG
  • DAIICHI SANKYO COMPANY, LIMITED
  • AbbVie Inc.
  • H. Lundbeck A/S
  • Biogen
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America dementia treatment market, by country, 2018 - 2030 (USD Million)
• Table 3 North America dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 4 North America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 5 North America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 6 North America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 U.S. dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 8 U.S. dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 9 U.S. dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 10 U.S. dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 Canada dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 12 Canada dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 13 Canada dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 14 Canada dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Europe dementia treatment market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 17 Europe dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 18 Europe dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 19 Europe dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Germany dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 21 Germany dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 22 Germany dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 23 Germany dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 UK dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 25 UK dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 26 UK dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 UK dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 France dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 29 France dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 30 France dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 31 France dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 32 Italy dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 33 Italy dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 34 Italy dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 35 Italy dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Spain dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 37 Spain dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 38 Spain dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 39 Spain dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Denmark dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 41 Denmark dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 42 Denmark dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Denmark dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 Sweden dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 45 Sweden dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 46 Sweden dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 47 Sweden dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Norway dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 49 Norway dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 50 Norway dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 51 Norway dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific dementia treatment market, by region, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 55 Aisa Pacific dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 56 Aisa Pacific dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 57 China dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 58 China dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 59 China dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 60 China dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Japan dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 62 Japan dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 63 Japan dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 64 Japan dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 India dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 66 India dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 67 India dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 68 India dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 South Korea dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 70 South Korea dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 71 South Korea dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 72 South Korea dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 73 Australia dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 74 Australia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 75 Australia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 76 Australia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77 Thailand dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 78 Thailand dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 79 Thailand dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 80 Thailand dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 81 Latin America dementia treatment market, by region, 2018 - 2030 (USD Million)
• Table 82 Latin America dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 83 Latin America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 84 Latin America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 85 Latin America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 86 Brazil dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 87 Brazil dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 88 Brazil dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 89 Brazil dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Mexico dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 91 Mexico dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 92 Mexico dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 93 Mexico dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 94 Argentina dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 95 Argentina dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 96 Argentina dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 97 Argentina dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 98 MEA dementia treatment market, by region, 2018 - 2030 (USD Million)
• Table 99 MEA dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 100 MEA dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 101 MEA dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 102 MEA dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 103 South Africa dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 104 South Africa dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 105 South Africa dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 106 South Africa dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 111 UAE dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 112 UAE dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 113 UAE dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 114 UAE dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 115 Kuwait dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 116 Kuwait dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 117 Kuwait dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 118 Kuwait dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Dementia treatment market: market outlook
• Fig. 14 Dementia treatment competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Dementia treatment market driver impact
• Fig. 18 Dementia treatment market restraint impact
• Fig. 19 Dementia treatment market: Indication movement analysis
• Fig. 20 Dementia treatment market: Indication outlook and key takeaways
• Fig. 21 Alzheimer's disease dementia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Vascular dementia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Lewy body dementia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Frontotemporal dementia (FTD) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Parkinson'skinson disease dementia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Dementia treatment market: Drug class movement analysis
• Fig. 28 Dementia treatment market: Drug class outlook and key takeaways
• Fig. 29 Cholinesterase inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 NMDA receptor antagonist market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 MAO inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Combination drug market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Dementia treatment market: Route of administration movement analysis
• Fig. 35 Dementia treatment market: Route of administration outlook and key takeaways
• Fig. 36 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Transdermal patch market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Dementia treatment market: Distribution channel movement analysis
• Fig. 40 Dementia treatment market: Distribution channel outlook and key takeaways
• Fig. 41 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Global dementia treatment market: Regional movement analysis
• Fig. 45 Global dementia treatment market: Regional outlook and key takeaways
• Fig. 46 Global dementia treatment market share and leading players
• Fig. 47 North America, by country
• Fig. 48 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 U.S. key country dynamics
• Fig. 50 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Canada key country dynamics
• Fig. 52 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 UK key country dynamics
• Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Germany key country dynamics
• Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 France key country dynamics
• Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Italy key country dynamics
• Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Spain key country dynamics
• Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Denmark key country dynamics
• Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Sweden key country dynamics
• Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Norway key country dynamics
• Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 China key country dynamics
• Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Japan key country dynamics
• Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 India key country dynamics
• Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Thailand key country dynamics
• Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 South Korea key country dynamics
• Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Australia key country dynamics
• Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Brazil key country dynamics
• Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Mexico key country dynamics
• Fig. 87 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Argentina key country dynamics
• Fig. 89 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 South Africa key country dynamics
• Fig. 92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Saudi Arabia key country dynamics
• Fig. 94 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 UAE key country dynamics
• Fig. 96 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Kuwait key country dynamics
• Fig. 98 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Market share of key market players- 2023

Dementia Treatment Market Growth & Trends:

The global dementia treatment market size is anticipated to reach USD 28.11 billion by 2030, registering a CAGR of 7.68% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing patient base of dementia, introduction of novel drugs, and increasing involvement of market players and research institutes to develop effective treatment for the disease are some of key factors driving market growth. According to the Cross River Therapy data published in September 2023, the prevalence of Alzheimer's disease (AD) in the UK is around 42.70 cases per 100,000 people, which makes it the country with the second-greatest number of cases per capita.

Increasing favorable initiatives undertaken by government and non-government bodies to support the awareness campaign and research activities to develop novel therapies for dementia treatment are anticipated to fuel market growth. For instance, in February 2022, McGill University's Dementia Education Program initiated 15 projects funded by the Public Health Agency of Canada to increase awareness about the disease. The Dementia Community Investment (DCI) is going to invest USD 758,430 to support the University's Ten Online Modules over Ten Weeks for Adult Learners (TOTAL) eLearning to spread awareness among caregivers.

Academic and research institutes are further involved in research activities to study different types of dementia and development of effective therapeutics to reduce the overall disease burden. For instance, in February 2024, researchers at the University of Colorado Anschutz Medical Campus found that Mdm2 protein with an investigational cancer drug, nutlin, can prevent the destruction of synapses and dendritic spines associated with Alzheimer's disease. Moreover, in December 2023, A preclinical study from the Perelman School of Medicine at the University of Pennsylvania showed that a chaperone molecule formulated specific proteins that can reverse disease signs including aging brain and memory impairment.

Market players are collaborating with regional players and research institutions to increase their capabilities to develop effective and safe therapy for dementia. In February 2021, Exscientia and the University of Oxford tied up to develop therapies for Alzheimer's disease. Moreover, Eisai Co., Ltd. and Biogen partnered to develop effective therapies for dementia earlier. These companies have jointly developed aducanumab and lecanemab. The companies are receiving market approvals for these drugs from key regulatory authorities across the globe.

Dementia Treatment Market Report Highlights:

• The AD dementia segment dominated the indication segment market with a share of 60.11% in 2023 owing to a high prevalence of AD dementia and approved drugs
• The Lewy body dementia (LBD) segment is expected to grow at the fastest CAGR from 2024 to 2030 owing to the increasing incidence and severity of the disease
• The cholinesterase inhibitors segment held the largest share in 2023 owing to high prescription rate of oral and transdermal patches of these drugs
• The combination drug segment is projected to experience the fastest CAGR from 2024 to 2030 owing to increased effectiveness and adoption of combination drugs
• The injectables route of administration segment is anticipated to register the fastest CAGR from 2024 to 2030 owing to the introduction of biological drugs and the presence of promising injectable drugs in the pipeline
• North America dominated the global market in 2023 owing to factors, such as high disease prevalence, presence of strong market players, and better reimbursement policies in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Indication and drug class outlook
  • 2.2.2. Route of administration and distribution channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Dementia Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of dementia
    • 3.2.1.2. Increasing government funding and awareness programs
    • 3.2.1.3. Surge in R&D activities
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High failure rates of drugs at approval stages
• 3.3. Dementia Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Dementia Treatment Market: Indication Estimates & Trend Analysis

• 4.1. Global Dementia Treatment Market: Indication Dashboard
• 4.2. Global Dementia Treatment Market: Indication Movement Analysis
• 4.3. Global Dementia Treatment Market by Indication, Revenue 2018 - 2030 (USD Million)
• 4.4. Alzheimer's Disease Dementia
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Vascular Dementia
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Lewy Body Dementia
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Frontotemporal Dementia (FTD)
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Parkinson's Disease Dementia
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Dementia Treatment Market: Drug Class Estimates & Trend Analysis

• 5.1. Global Dementia Treatment Market: Drug Class Dashboard
• 5.2. Global Dementia Treatment Market: Drug Class Movement Analysis
• 5.3. Global Dementia Treatment Market by Drug Class, Revenue 2018 - 2030 (USD Million)
• 5.4. Cholinesterase Inhibitors
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. NMDA Receptor Antagonist
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. MAO Inhibitors
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Combination Drug
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Dementia Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Dementia Treatment Market: Route of Administration Dashboard
• 6.2. Global Dementia Treatment Market: Route of Administration Movement Analysis
• 6.3. Global Dementia Treatment Market by Route of Administration, Revenue 2018 - 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Transdermal Patch
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Injectable
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Dementia Treatment Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global Dementia Treatment Market: Distribution Channel Dashboard
• 7.2. Global Dementia Treatment Market: Distribution Channel Movement Analysis
• 7.3. Global Dementia Treatment Market by Distribution Channel, Revenue 2018 - 2030 (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Online Pharmacy
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Dementia Treatment Market: Regional Estimates & Trend Analysis by Indication, Drug Class, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Mexico
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Eisai Co., Ltd.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Lilly
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Novartis AG
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. DAIICHI SANKYO COMPANY, LIMITED
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. AbbVie Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. H. Lundbeck A/S
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Biogen
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Cipla Inc.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Sun Pharmaceutical Industries Ltd.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Viatris Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives